The purpose of this Question Verification Form is to enable Priority Setting Partnerships (PSPs) to describe clearly how they checked that their questions were unanswered, before starting the interim prioritisation stage of the process.
The JLA requires PSPs to be transparent and accountable in defining their own scope and evidence checking process. This will enable researchers and other stakeholders to understand how individual PSPs decided that their questions were unanswered, and any limitations of their evidence checking.
Name of the PSP
Psoriatic Arthritis Priority Setting Partnership
Please describe the scope of the PSP
The aim of the Psoriatic Arthritis (PsA) PSP is to identify the unanswered questions about psoriatic arthritis from patient, carer and clinical perspectives and then prioritise those that patients, carers and clinicians agree are the most important for research to address.
The objectives of the PSP are to:
- work with patients and their families, carers and clinicians to identify uncertainties about psoriatic arthritis including:
- prevention
- diagnosis and referral;
- all severities of disease;
- peripheral arthritis, enthesitis, axial disease, dactylitis, psoriasis and nail disease;
- symptoms and disease impact (e.g. fatigue, functional ability, practical impacts);
- assessment of disease activity and impact;
- associated conditions (including SpA-related conditions and other comorbidities);
- treatments;
- management strategies;
- monitoring and treatment of flare;
- impact of lifestyle change on symptoms and outcomes (e.g. diet, smoking, exercise).
- to agree by consensus a prioritised list of those uncertainties, for research to publicise the results of the PSP and process.
- to take the results to research commissioning bodies to be considered for funding.
The PSP will exclude from its scope questions about:
- PsA in people under 16 years old/juvenile PsA/juvenile idiopathic arthritis (JIA) with psoriasis.
Please provide a brief overview of your approach to checking whether the questions were unanswered
For reasons of practicality the steering group agreed to search for systematic reviews and guidelines that had been published during the last three years. The search strategy was developed using keywords, free text and MeSH terms where they were available. Endorsed search filters were incorporated into the strategy to allow a highly focused and targeted searches to identify systematic reviews and guidelines:
- McMaster systematic review filter (for MEDLINE OVID) maximises specificity (modified to include new SR publication type heading introduced in 2019)https://hiru.mcmaster.ca/hiru/HIRU_Hedges_MEDLINE_Strategies.aspx#Reviews
- ASTED(3S)/CHLA Guidelines search filter [2018] for MEDLINE via OVID http://extranet.santecom.qc.ca/wiki/!biblio3s/doku.php?id=concepts:lignes-directrices
The search strategy for the evidence check was tested on 7 January 2021 before a final review at the PsA PSP steering group meeting in January 2021.
Please list the type(s) of evidence you used to verify your questions as unanswered
- Systematic reviews.
- Royal College Guidelines (British Society for Rheumatology) and NICE Guidelines.
Please list the sources that you searched in order to identify that evidence
Databases and platforms:
- Medline (Ovid MEDLINE® Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE® Daily and Ovid MEDLINE®) 1946 to present.
- The Cochrane Database of Systematic Reviews https://www.cochranelibrary.com/cdsr/reviews.
- NHS Evidence (for “guidance and policy”) https://www.evidence.nhs.uk.
- WHO ICTRP https://apps.who.int/trialsearch/.
- PROSPERO https://www.crd.york.ac.uk/prospero/.
- Relevant Royal College Guidelines (British Society for Rheumatology).
What search terms did you use?
MEDLINE search terms:
1 Arthritis, Psoriatic/
2 exp Arthritis/ and Psoriasis/
3 Enthesopathy/
4 psoriat*.ti,ab,kf.
5 enthesitis.ti,ab,kf.
6 enthesopath*.ti,ab,kf.
7 dactylitis.ti,ab,kf.
8 ((psorias* or nail*) adj5 (arthrit* or arthropath* or monoarthr* or oligoarthr* or polyarthr* or rheumat*)).ti,ab,kf.
9 ((psorias* or nail*) adj5 (axial or peripheral or spondyl?arthr* or arthropath* or spondylitis or sacroili?ti*)).ti,ab,kf.
10 (psorias* or nail*).ti,ab,kf. and (spondylarthropathies/ or Spondylarthritis/ or spondylitis, ankylosing/ or sacroiliitis/)
11 axPsA.ti,ab,kf.
12 pPsA.ti,ab,kf.
13 or/1-12
14 MEDLINE.tw.
15 systematic review.tw.
16 meta analysis.pt.
17 systematic review.pt.
18 or/14-18
19 (guideline* or guidance).ti,ab.
20 practice adj2 (guide*1 or recommend* or standard*)).ti,ab.
21 decision* adj2 (making or make*)).ti,ab.
22 (evidence-based adj2 (practice* or medicine or nursing)).ti,ab.
23 exp Guidelines as topic/
24 exp Guideline/
25 or/19-24
26 18 or 25
27 13 and 26
28 (Animals/ NOT (Animals/ AND Humans/))
29 27 not 28
30 Limit 29 to yr="2018-2021"
- The Cochrane Database of Systematic Reviews (for systematic reviews in the last 3 years)
Search term(s): "psoriatic arthritis" and “MeSH descriptor: Arthritis, Psoriatic”
https://www.cochranelibrary.com/cdsr/reviews - NHS Evidence (for “guidance and policy” in the last 3 years)
Search term(s): “psoriatic arthritis”
https://www.evidence.nhs.uk - WHO ICTRP (for pending trials)
Search term(s): “psoriatic arthritis”
https://apps.who.int/trialsearch/ - PROSPERO (for pending systematic reviews)
Search term(s): MeSH DESCRIPTOR Arthritis, Psoriatic EXPLODE ALL TREES
https://www.crd.york.ac.uk/prospero/ - Relevant Royal College Guidelines (British Society for Rheumatology)
Please describe the parameters of the search (e.g. time limits, excluded sources, country/language) and the rationale for any limitations
Time limit: the last 3 years (January 1, 2018 - February 4, 2021)
Names of individuals who undertook the evidence checking
Louise Hailey
On what date was the question verification process completed?
14 April, 2021
Any other relevant information
No